RU95122391A - ADJUVENTS FOR VACCINE AGAINST RESPIRATORY-SYNCITIAL VIRUS - Google Patents

ADJUVENTS FOR VACCINE AGAINST RESPIRATORY-SYNCITIAL VIRUS

Info

Publication number
RU95122391A
RU95122391A RU95122391/14A RU95122391A RU95122391A RU 95122391 A RU95122391 A RU 95122391A RU 95122391/14 A RU95122391/14 A RU 95122391/14A RU 95122391 A RU95122391 A RU 95122391A RU 95122391 A RU95122391 A RU 95122391A
Authority
RU
Russia
Prior art keywords
rsv
glycoprotein
vaccine composition
protein
composition according
Prior art date
Application number
RU95122391/14A
Other languages
Russian (ru)
Other versions
RU2160119C2 (en
Inventor
Е.Хэнкок Джеральд
Дж.Спилмэн Дэн
Дж.Френчик Патрик
Original Assignee
Американ Цианамид Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Американ Цианамид Компани filed Critical Американ Цианамид Компани
Publication of RU95122391A publication Critical patent/RU95122391A/en
Application granted granted Critical
Publication of RU2160119C2 publication Critical patent/RU2160119C2/en

Links

Claims (11)

1. Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (РСВ) или его иммунологический фрагмент и адъювант, выбираемый из группы, состоящей из QS-21, монофосфориллипида А, 3-деацилированного монофосфориллипида А и их сочетаний, в физиологически приемлемом носителе.1. A vaccine composition comprising a respiratory syncytial virus (RSV) protein or immunological fragment and an adjuvant selected from the group consisting of QS-21, monophosphoryl lipid A, 3-deacylated monophosphoryl lipid A and combinations thereof, in a physiologically acceptable carrier. 2. Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (РСВ) или его иммунологический фрагмент и QS-21, в физиологически приемлемом носителе. 2. A vaccine composition comprising a respiratory syncytial virus (RSV) protein or immunological fragment thereof and QS-21 in a physiologically acceptable carrier. 3. Вакцинная композиция по п. 1, отличающаяся тем, что содержит также алюм (гидроксид алюминия). 3. The vaccine composition according to claim 1, characterized in that it also contains aluminum (aluminum hydroxide). 4. Вакцинная композиция по п. 2, отличающаяся тем, что содержит также алюм. 4. The vaccine composition according to claim 2, characterized in that it also contains aluminum. 5. Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (РСВ) или его иммунологический фрагмент, алюм и 3-деацилированный монофосфориллипид А, в физиологически приемлемом носителе. 5. A vaccine composition containing a respiratory syncytial virus (RSV) protein or immunological fragment thereof, alum and 3-deacylated monophosphoryl lipid A, in a physiologically acceptable carrier. 6. Вакцинная композиция по п. 1, отличающаяся тем, что белок РСВ выбирают из группы, состоящей из гликопротеина G РСВ, гликопротеина F РСВ, химерного полипептида, содержащего по крайней мере один иммуногенный фрагмент из обоих гликопротеинов РСВ - F и G, и их сочетаний. 6. The vaccine composition according to claim 1, wherein the RSV protein is selected from the group consisting of glycoprotein G RSV, glycoprotein F RSV, a chimeric polypeptide containing at least one immunogenic fragment of both RSV glycoproteins - F and G, and combinations. 7. Вакцинная композиция по п. 2, отличающаяся тем, что белок РСВ выбирают из группы, состоящей из гликопротеина G РСВ, гликопротеина F РСВ, химерного полипептида, содержащего по крайней мере один иммуногенный фрагмент из обоих гликопротеинов РСВ - F и G, и их сочетаний. 7. The vaccine composition according to claim 2, wherein the RSV protein is selected from the group consisting of glycoprotein G RSV, glycoprotein F RSV, a chimeric polypeptide containing at least one immunogenic fragment of both RSV glycoproteins - F and G, and combinations. 8. Вакцинная композиция по п. 3, отличающаяся тем, что белок РСВ выбирают из группы, состоящей из гликопротеина G РСВ, гликопротеина F РСВ, химерного полипептида, содержащего по крайней мере один иммуногенный фрагмент из обоих гликопротеинов РСВ - F и G, и их сочетаний. 8. The vaccine composition according to claim 3, wherein the RSV protein is selected from the group consisting of glycoprotein G RSV, glycoprotein F RSV, a chimeric polypeptide containing at least one immunogenic fragment of both RSV glycoproteins - F and G, and their combinations. 9. Вакцинная композиция по п. 4, отличающаяся тем, что белок РСВ выбирают из группы, состоящей из гликопротеина G РСВ, гликопротеина F РСВ, химерного полипептида, содержащего по крайней мере один иммуногенный фрагмент из обоих гликопротеинов РСВ - F и G, и их сочетаний. 9. The vaccine composition according to claim 4, characterized in that the RSV protein is selected from the group consisting of glycoprotein G RSV, glycoprotein F RSV, a chimeric polypeptide containing at least one immunogenic fragment of both RSV glycoproteins - F and G, and combinations. 10. Вакцинная композиция по п. 5, отличающаяся тем, что белок РСВ выбирают из группы, состоящей из гликопротеина G РСВ, гликопротеина F РСВ, химерного полипептида, содержащего по крайней мере один иммуногенный фрагмент из обоих гликопротеинов РСВ - F и G, и их сочетаний. 10. The vaccine composition according to claim 5, characterized in that the RSV protein is selected from the group consisting of glycoprotein G RSV, glycoprotein F RSV, a chimeric polypeptide containing at least one immunogenic fragment of both RSV glycoproteins - F and G, and combinations. 11. Способ предупреждения инфекции или симптомов заболевания, связанных с респираторно-синцитиальным вирусом, у особи, отличающийся тем, что включает введение эффективного количества вакцины по пп. 1, 2, 3, 4, 5, 6, 7, 8, 9 или 10. 11. A method for preventing infection or symptoms of a disease associated with a respiratory syncytial virus in an individual, characterized in that it comprises administering an effective amount of a vaccine according to claims. 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
RU95122391/14A 1993-05-25 1994-05-24 Vaccine composition containing respiratory-syncytial virus protein (versions) RU2160119C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6785593A 1993-05-25 1993-05-25
US08/067.855 1993-05-25
US08/067,855 1993-05-25

Publications (2)

Publication Number Publication Date
RU95122391A true RU95122391A (en) 1998-02-10
RU2160119C2 RU2160119C2 (en) 2000-12-10

Family

ID=22078872

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95122391/14A RU2160119C2 (en) 1993-05-25 1994-05-24 Vaccine composition containing respiratory-syncytial virus protein (versions)

Country Status (15)

Country Link
US (1) US5723130A (en)
EP (1) EP0705109B2 (en)
JP (1) JP3734263B2 (en)
AT (1) ATE196737T1 (en)
AU (1) AU676340B2 (en)
CA (1) CA2163550A1 (en)
DE (1) DE69426077T3 (en)
DK (1) DK0705109T4 (en)
ES (1) ES2150493T5 (en)
FI (1) FI955667A (en)
GR (1) GR3034785T3 (en)
NO (1) NO954786L (en)
PT (1) PT705109E (en)
RU (1) RU2160119C2 (en)
WO (1) WO1994027636A1 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE322289T1 (en) * 1994-10-05 2006-04-15 Univ Vanderbilt INTERLEUKIN-12 AS AN ADJUVANT FOR PARAMYOXVIRIDAE VACCINES
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6975708B1 (en) * 1996-04-17 2005-12-13 Convergys Cmg Utah, Inc. Call processing system with call screening
US5867562A (en) * 1996-04-17 1999-02-02 Scherer; Gordon F. Call processing system with call screening
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation
DE69720024D1 (en) * 1996-07-12 2003-04-24 Aventis Pasteur IMMUNIZATION PROCEDURE IN TWO STEPS AGAINST PYRAMYXOVIRIDAE VIRUSES USING ATTENUATED VIRAL STRAINS AND PREPARATION OF PROTEIN SUB-UNITS
US6180398B1 (en) * 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
ES2296390T3 (en) * 1998-05-07 2008-04-16 Corixa Corporation COMPOSITION COADYUVANTE AND PROCEDURE FOR USE.
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CA2365411A1 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
JP2002540171A (en) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ Attenuated dengue type 4 virus vaccine
TR200103266T2 (en) * 1999-05-13 2002-01-21 American Cyanamid Company Auxiliary combination formulations
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2001097841A2 (en) * 2000-06-22 2001-12-27 American Cyanamid Company Qs-21 and il-12 as an adjuvant combination
US7229623B1 (en) * 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
EA004744B1 (en) * 2000-11-10 2004-08-26 Уайт Холдингз Корпорейшн Adjuvant combination formulations
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE10205373B4 (en) * 2002-02-09 2007-07-19 Aloys Wobben Fire protection
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BRPI0407058A (en) * 2003-02-01 2006-01-17 Neuralab Ltd Methods of prophylaxis and treatment of a disease, pharmaceutical composition, and use of a fragment
US20060095001A1 (en) * 2004-10-29 2006-05-04 Transcutaneous Technologies Inc. Electrode and iontophoresis device
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
JP2006346368A (en) * 2005-06-20 2006-12-28 Transcutaneous Technologies Inc Iontophoresis apparatus and manufacturing method
JP2007000342A (en) * 2005-06-23 2007-01-11 Transcutaneous Technologies Inc Iontophoresis device for controlling quantity and time of dosing a plurality of medicaments
US8295922B2 (en) 2005-08-08 2012-10-23 Tti Ellebeau, Inc. Iontophoresis device
US8386030B2 (en) * 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US20070088332A1 (en) * 2005-08-22 2007-04-19 Transcutaneous Technologies Inc. Iontophoresis device
US20090254018A1 (en) * 2005-08-24 2009-10-08 Mizuo Nakayama Electrode assembly for freezing-type iontophoresis device
US20070048362A1 (en) * 2005-08-29 2007-03-01 Transcutaneous Technologies Inc. General purpose electrolyte solution composition for iontophoresis
JPWO2007029611A1 (en) * 2005-09-06 2009-03-19 Ｔｔｉ・エルビュー株式会社 Iontophoresis device
US20070112294A1 (en) * 2005-09-14 2007-05-17 Transcutaneous Technologies Inc. Iontophoresis device
JPWO2007032446A1 (en) * 2005-09-15 2009-03-19 Ｔｔｉ・エルビュー株式会社 Rod iontophoresis device
CN101262905A (en) * 2005-09-16 2008-09-10 Tti优而美株式会社 Catheter type iontophoresis apparatus
WO2007037324A1 (en) * 2005-09-28 2007-04-05 Transcu Ltd. Dry electrode construct for iontophoresis
JP2009509634A (en) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 Functionalized microneedle transdermal drug delivery system, apparatus and method
WO2007037476A1 (en) * 2005-09-30 2007-04-05 Tti Ellebeau, Inc. Iontophoresis apparatus capable of controlling dose and timing of administration of sleep inducer and analeptic agent
WO2007037475A1 (en) * 2005-09-30 2007-04-05 Tti Ellebeau, Inc. Electrode structure for iontophoresis comprising shape memory separator, and iontophoresis apparatus comprising the same
KR20080066712A (en) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 Functionalized microneedles transdermal drug delivery systems, devices, and methods
EP1931417A2 (en) * 2005-09-30 2008-06-18 Transcutaneous Technologies Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
EP1928542A1 (en) * 2005-09-30 2008-06-11 Tti Ellebeau, Inc. Method and system to detect malfunctions in an iontophoresis device that delivers active agents to biological interfaces
CN101277737A (en) * 2005-09-30 2008-10-01 Tti优而美株式会社 Iontophoresis device to deliver multiple active agents to biological interfaces
JP2009509677A (en) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 Iontophoretic delivery of vesicle encapsulated active substances
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
US20070197955A1 (en) * 2005-10-12 2007-08-23 Transcutaneous Technologies Inc. Mucous membrane adhesion-type iontophoresis device
US20080033338A1 (en) * 2005-12-28 2008-02-07 Smith Gregory A Electroosmotic pump apparatus and method to deliver active agents to biological interfaces
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
JP2010502293A (en) * 2006-09-05 2010-01-28 Ｔｔｉ・エルビュー株式会社 Transdermal drug delivery system, apparatus and method using inductive power supply
JP5383497B2 (en) 2006-12-01 2014-01-08 Ｔｔｉ・エルビュー株式会社 System and device for powering and / or controlling a device, for example a transdermal delivery device
AU2008242648B2 (en) * 2007-04-18 2013-09-12 Janssen Alzheimer Immunotherapy Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US7736648B2 (en) * 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20100312168A1 (en) * 2009-06-09 2010-12-09 Yoshimasa Yoshida Long life high capacity electrode, device, and method of manufacture
US8883717B2 (en) 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
US9433671B2 (en) 2012-03-30 2016-09-06 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
CA2981359C (en) * 2015-04-16 2023-06-27 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
EP3349788A4 (en) 2015-09-16 2019-06-05 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
JP2021533157A (en) * 2018-08-07 2021-12-02 ウィスコンシン アルムニ リサーチ ファンデイション Recombinant biologically contained filovirus vaccine
CN113874496A (en) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) Humanized cell lines
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1188985A (en) † 1980-07-01 1985-06-18 Edward J. Stott Production of viral antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2716503B2 (en) * 1987-12-23 1998-02-18 ジ・アップジョン・カンパニー Chimeric glycoproteins containing immunogenic segments of human respiratory syncytial virus glycoproteins.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9120221D0 (en) † 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds
EP0812593B8 (en) * 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a

Similar Documents

Publication Publication Date Title
RU95122391A (en) ADJUVENTS FOR VACCINE AGAINST RESPIRATORY-SYNCITIAL VIRUS
DE69426077D1 (en) ADJUVANTIES FOR VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS
RU98101249A (en) OMR26 ANTIGEN HAEMOPHYLUS INFLUENZAE
RU2000116260A (en) LTB ADJUVANT VACCINES
RU2002113920A (en) ANTIGENIC PEPTIDES NEISSERIA
EP0592546A4 (en) Immunodeficiency virus recombinant poxvirus vaccine.
WO1997001640A3 (en) Vaccines against hepatitis c
RU2002132831A (en) VACCINE FORMULA AGAINST RESPIRATORY PATHOLOGIES OF CATTLE
DE69634024D1 (en) Adjuvant for vital vaccines
EP0495008A4 (en) Method of treatment
CA2129747A1 (en) Peptide for diagnosing and immunizing against t. cruzi infection
RU98118186A (en) VACCINE AGAINST REPRODUCTIVE AND RESPIRATORY SYNDROME IN PIG
CA2639048A1 (en) Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis
CA2302833A1 (en) Peptides derived from the attachment (g) protein of respiratory syncytial virus
DE3751772T2 (en) Vaccine for the treatment of HSV
ATE154244T1 (en) INDUCING PROTECTION AGAINST VIRAL INFECTIONS
EP0317622A4 (en) Prevention and treatment of retroviral disease.
NZ224251A (en) Synthetic rhinovirus (hrv) peptides and vaccines
ES515472A0 (en) PROCEDURE TO PROTECT SUSCEPTIBLE HOSTS FROM HEPATITIS INFECTION.
ES2052273T3 (en) COMPOSITION CONTAINING AN EPITOPE B OF THE GLYCOPROTEIN ENVELOPING A RETROVIRUS AND AN EPITOPE T OF A PROTEIN DIFFERENT FROM SUCH RETROVIRUSES.
RU98105627A (en) VACCINES
RU94032103A (en) PEPTIDES, PHARMACEUTICAL COMPOSITION, VACCINE, CONJUGAT, TREATMENT METHODS AND IDENTIFICATION